The Impact of the COVID-19 Pandemic on Osteoporosis Diagnosis and Treatment in Iran: A National Study

The present study demonstrated that the COVID-19 pandemic negatively affected the diagnosis and treatment of osteoporosis. However, it was limited by the lack of data on prescriptions for other osteoporosis medications and diagnostic tests, the lack of access to the data on prescriptions for people whose costs are not covered by the IHIO, and the restricted data access regarding the presented data. The findings are based on prescription-level data in Iran and primarily reflect practice within this healthcare context; therefore, caution is required when generalizing to settings with different healthcare systems or population structures. Further studies are needed to assess this impact and to help prevent management disruption in future health crises.

Authors

Institutions

Publication Details

Journal
International Journal of Endocrinology and Metabolism
Published
2025-10-31
DOI
https://doi.org/10.5812/ijem-165816
Primary Topic
Bone health and osteoporosis research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Impact of the COVID-19 Pandemic on Osteoporosis Diagnosis and Treatment in Iran: A National Study

Fatemeh Hajivalizadeh, Kazem Khalagi, Noushin Fahimfar, Mahnaz Sanjari et al.
International Journal of Endocrinology and Metabolism
Bone health and osteoporosis research
article

The Impact of the COVID-19 Pandemic on Osteoporosis Diagnosis and Treatment in Iran: A National Study

Fatemeh Hajivalizadeh, Kazem Khalagi, Noushin Fahimfar, Mahnaz Sanjari, Amirhossein Aghakhani, Afshin Ostovar, Mohammad Javad Mansourzadeh, Elahe Hesari, Zahra Shahali, Sepideh Hajivalizadeh, Parastoo Montazerlotf, Mohammad Effatpanah, Pardis Zarepour, Saeed Shahsavari
article en

Abstract

The present study demonstrated that the COVID-19 pandemic negatively affected the diagnosis and treatment of osteoporosis. However, it was limited by the lack of data on prescriptions for other osteoporosis medications and diagnostic tests, the lack of access to the data on prescriptions for people whose costs are not covered by the IHIO, and the restricted data access regarding the presented data. The findings are based on prescription-level data in Iran and primarily reflect practice within this healthcare context; therefore, caution is required when generalizing to settings with different healthcare systems or population structures. Further studies are needed to assess this impact and to help prevent management disruption in future health crises.

International Journal of Endocrinology and MetabolismVol. 23(4)
Imam Khomeini Hospital (IR), Research Institute for Endocrine Sciences (IR), Jahrom University of Medical Sciences (IR), Ministry of Health and Medical Education (IR), Center for Non-Communicable Diseases (PK), Alborz University of Medical Sciences (IR), Shahid Beheshti University of Medical Sciences (IR), Tehran University of Medical Sciences (IR)
Good health and well-being
Openalex Percentile: Top 29%
Bone health and osteoporosis research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.